Glycopyrronium Xiromed (Glycopyrronium Bromide)

Glycopyrronium Xiromed is indicated for the long‑term, once‑daily maintenance treatment of airflow limitation in patients with chronic obstructive pulmonary disease (COPD).

• Daily maintenance therapy to reduce breathlessness, wheeze, and cough associated with COPD.
• Improves lung function measurements such as forced expiratory volume in one second (FEV1).
• Helps lower the risk of moderate or severe COPD exacerbations requiring medical intervention.
• Can be prescribed as monotherapy or combined with a long‑acting β2‑agonist for enhanced bronchodilation.
• Appropriate for patients with moderate to severe airflow obstruction who require a long‑acting anticholinergic agent.

The safety profile of Glycopyrronium Xiromed includes both common and less frequent serious adverse events observed in clinical use, most of which are mild and reversible.

Common

• Dry mouth – reduced saliva, usually mild.
• Cough – brief coughing after inhalation.
• Throat irritation – mild discomfort in throat.
• Upper respiratory tract infection – nasal congestion or sore throat.
• Headache – mild to moderate head pain.

Serious

• Acute narrow‑angle glaucoma – sudden eye pain and visual changes.
• Urinary retention – difficulty starting or maintaining urine flow.
• Severe allergic reactions – rash, swelling, or anaphylaxis.

Before prescribing Glycopyrronium Xiromed, clinicians should consider several precautionary measures to ensure safe use in patients with COPD.

• Assess for a history of narrow‑angle glaucoma before initiating therapy.
• Use caution in patients with urinary retention or prostate enlargement.
• Monitor renal function, as the drug is primarily excreted unchanged by the kidneys.
• Evaluate cardiovascular status, especially in patients with arrhythmias or recent myocardial infarction.
• Advise patients to report persistent dry mouth or difficulty swallowing.
• Educate patients on proper inhaler technique to minimize local irritation.

Glycopyrronium Xiromed may interact with other medications; awareness of potential interactions helps avoid reduced efficacy or increased adverse effects.

Avoid

• Other anticholinergic inhalers (e.g., tiotropium) due to additive anticholinergic effects.
• Strong systemic anticholinergics (e.g., atropine) that may exacerbate dry mouth and urinary retention.

Use with caution

• Long‑acting β2‑agonists (LABA) when combined, monitor for bronchospasm.
• Cholinesterase inhibitors used in Alzheimer’s disease (e.g., donepezil) as they may counteract bronchodilation.
• Medications that affect renal excretion (e.g., NSAIDs) may alter drug clearance.
• Diuretics that may cause electrolyte imbalance, potentially increasing risk of cardiac arrhythmias.